よむ、つかう、まなぶ。
03 資料１－１ 帯状疱疹ワクチンファクトシート (77 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_40826.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第26回 6／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
virus seronegative and low-seropositive healthy adults. Vaccine 2007; 25(11): 2139-44.
176.
Perciani CT, Sekhon M, Hundal S, et al. Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.
J Infect Dis 2018; 218(8): 1210-8.
177.
Huang L, Chen Z, Song Y, et al. Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy
population aged 13 years and older: A randomized, double-blind, controlled study. Vaccine 2024; 42(2): 396-401.
178.
Harbecke R, Cohen JI, Oxman MN. Herpes Zoster Vaccines. J Infect Dis 2021; 224(12 Suppl 2): S429-s42.
179.
Choi WS, Choi JH, Choi JY, et al. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine
(ZOSTAVAX™) in Korean Adults. J Korean Med Sci 2016; 31(1): 13-7.
180.
Phillips A, Glover C, Leeb A, et al. Safety of live attenuated herpes zoster vaccine in Australian adults 70-79 years
of age: an observational study using active surveillance. BMJ Open 2021; 11(3): e043880.
181.
Totterdell J, Phillips A, Glover C, et al. Safety of live attenuated herpes zoster vaccine in adults 70-79 years: A
self-controlled case series analysis using primary care data from Australia's MedicineInsight program. Vaccine 2020;
38(23): 3968-79.
182.
Sreenivasamurthy L, Pandey S, Chandra BS, et al. Immunogenicity, Safety, and Tolerability of Live Attenuated
VaricellaZoster Virus Vaccine (ZOSTAVAX™) in Healthy Adults in India. J Assoc Physicians India 2018; 66(7): 504.
183.
Tseng HF, Schmid DS, Harpaz R, et al. Herpes zoster caused by vaccine-strain varicella zoster virus in an
immunocompetent recipient of zoster vaccine. Clin Infect Dis 2014; 58(8): 1125-8.
184.
Yao CA, Chen LK, Huang KC. The immunogenicity and safety of zoster vaccine in Taiwanese adults. Vaccine
2015; 33(13): 1515-7.
185.
Sutradhar SC, Wang WW, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax
in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol 2009; 16(5): 646-52.
186.
Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a
history of herpes zoster. Vaccine 2010; 28(25): 4204-9.
187.
Moro PL, Leung J, Marquez P, et al. Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event
Reporting System, United States, 2006-2020. J Infect Dis 2022; 226(Suppl 4): S431-s40.
188.
Xia Y, Zhang X, Zhang L, Fu C. Efficacy, effectiveness, and safety of herpes zoster vaccine in the
immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. Front
Immunol 2022; 13: 978203.
189.
Marra Y, Lalji F. Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines.
Viruses 2022; 14(12).
190.
Chacón GR, Sinha AA. Bullous pemphigoid after herpes zoster vaccine administration: association or
coincidence? J Drugs Dermatol 2011; 10(11): 1328-30.
191.
Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum
Vaccin 2011; 7(11): 1130-6.
192.
Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented
herpes zoster. J Infect Dis 2013; 208(4): 559-63.
76
176.
Perciani CT, Sekhon M, Hundal S, et al. Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.
J Infect Dis 2018; 218(8): 1210-8.
177.
Huang L, Chen Z, Song Y, et al. Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy
population aged 13 years and older: A randomized, double-blind, controlled study. Vaccine 2024; 42(2): 396-401.
178.
Harbecke R, Cohen JI, Oxman MN. Herpes Zoster Vaccines. J Infect Dis 2021; 224(12 Suppl 2): S429-s42.
179.
Choi WS, Choi JH, Choi JY, et al. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine
(ZOSTAVAX™) in Korean Adults. J Korean Med Sci 2016; 31(1): 13-7.
180.
Phillips A, Glover C, Leeb A, et al. Safety of live attenuated herpes zoster vaccine in Australian adults 70-79 years
of age: an observational study using active surveillance. BMJ Open 2021; 11(3): e043880.
181.
Totterdell J, Phillips A, Glover C, et al. Safety of live attenuated herpes zoster vaccine in adults 70-79 years: A
self-controlled case series analysis using primary care data from Australia's MedicineInsight program. Vaccine 2020;
38(23): 3968-79.
182.
Sreenivasamurthy L, Pandey S, Chandra BS, et al. Immunogenicity, Safety, and Tolerability of Live Attenuated
VaricellaZoster Virus Vaccine (ZOSTAVAX™) in Healthy Adults in India. J Assoc Physicians India 2018; 66(7): 504.
183.
Tseng HF, Schmid DS, Harpaz R, et al. Herpes zoster caused by vaccine-strain varicella zoster virus in an
immunocompetent recipient of zoster vaccine. Clin Infect Dis 2014; 58(8): 1125-8.
184.
Yao CA, Chen LK, Huang KC. The immunogenicity and safety of zoster vaccine in Taiwanese adults. Vaccine
2015; 33(13): 1515-7.
185.
Sutradhar SC, Wang WW, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax
in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol 2009; 16(5): 646-52.
186.
Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a
history of herpes zoster. Vaccine 2010; 28(25): 4204-9.
187.
Moro PL, Leung J, Marquez P, et al. Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event
Reporting System, United States, 2006-2020. J Infect Dis 2022; 226(Suppl 4): S431-s40.
188.
Xia Y, Zhang X, Zhang L, Fu C. Efficacy, effectiveness, and safety of herpes zoster vaccine in the
immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis. Front
Immunol 2022; 13: 978203.
189.
Marra Y, Lalji F. Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines.
Viruses 2022; 14(12).
190.
Chacón GR, Sinha AA. Bullous pemphigoid after herpes zoster vaccine administration: association or
coincidence? J Drugs Dermatol 2011; 10(11): 1328-30.
191.
Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum
Vaccin 2011; 7(11): 1130-6.
192.
Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented
herpes zoster. J Infect Dis 2013; 208(4): 559-63.
76